Nektar Therapeutics (NKTR) EBIT Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly EBIT Margin of 359.58% for Q1 2026, up 6618.0% year-over-year from 5.35% in Q1 2025, and down 183.44% quarter-over-quarter from 126.86% in Q4 2025.
Nektar Therapeutics (NKTR) EBIT Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 359.58% for Q1 2026.
- In Q1 2026, EBIT Margin rose 6618.0% year-over-year to 359.58%; the TTM figure through Mar 2026 stood at 241.98% (down 11097.0% YoY), while the FY2025 annual figure was 253.66%, down 14678.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 359.58%, down from 126.86% in the prior quarter.
- The five-year high for EBIT Margin was 49.18% in Q4 2024, with the low at 708.07% in Q2 2022.
- The 5-year median for EBIT Margin is 238.25% (2022), against an average of 283.32%.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin plunged 31906 bps in 2022, then surged 46123 bps in 2023.
- Nektar Therapeutics' EBIT Margin stood at 238.25% in 2022, then soared by 41 bps to 140.3% in 2023, then soared by 135 bps to 49.18% in 2024, then slumped by 358 bps to 126.86% in 2025, then tumbled by 183 bps to 359.58% in 2026.
- Business Quant data shows NKTR's EBIT Margin at 359.58% in Q1 2026, 126.86% in Q4 2025, and 268.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -359.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -359.58% |
| Dec 31, 2025 | -126.86% |
| Sep 30, 2025 | -268.63% |
| Jun 30, 2025 | -324.21% |
| Mar 31, 2025 | -425.76% |
| Dec 31, 2024 | 49.18% |
| Sep 30, 2024 | -142.37% |
| Jun 30, 2024 | -211.90% |
| Mar 31, 2024 | -163.72% |
| Dec 31, 2023 | -140.30% |
| Sep 30, 2023 | -185.82% |
| Jun 30, 2023 | -246.84% |
| Mar 31, 2023 | -623.83% |
| Dec 31, 2022 | -238.25% |
| Sep 30, 2022 | -229.85% |
| Jun 30, 2022 | -708.07% |
| Mar 31, 2022 | -469.58% |
| Dec 31, 2021 | -451.48% |
| Sep 30, 2021 | -455.82% |
| Jun 30, 2021 | -389.00% |